Pharmicell Posts KRW 38.2B Operating Profit in First Nine Months, Up 55% YoY

Pharmicell sharply increased both revenue and operating profit in the first three quarters of this year, driven by growth in its electronic materials business. Revenue for the period came close to its full-year total for last year.

Pharmicell said on November 12 that it recorded revenue of KRW 112.6 billion and operating profit of KRW 38.2 billion in the first three quarters of this year. Compared with the same period last year, revenue rose 42% and operating profit increased 55%. Revenue and operating profit for the same period last year were KRW 79.4 billion and KRW 24.6 billion, respectively.

Standalone third-quarter results also continued to grow. Revenue was KRW 36.9 billion, up 44% from the same period last year, while operating profit increased 47% to KRW 11.9 billion.

Revenue for the first three quarters came close to last year's full-year revenue of KRW 114 billion. Sales of electronic materials used in advanced information technology (IT) infrastructure, as well as pharmaceutical raw materials such as nucleosides and mPEG, supported growth.

The Biomedical Division also grew. Its revenue for the first three quarters, including stem cell therapies, cosmetics, contract manufacturing (CMO) and contract testing services, was KRW 2.6 billion, up approximately 39% from the same period last year.

Pharmicell is building its third plant in Ulsan to meet rising demand for materials used in advanced AI industries and pharmaceutical raw materials. The third plant is targeted for completion by the end of January 2027, after which the company plans to expand production capacity.

A Pharmicell representative said, "Our core businesses, including electronic materials, continue to grow. We will strengthen the competitiveness of our core businesses while working to improve results in the Biomedical Division by expanding our bio CMO business."

This content was produced with the assistance of AI translation services.